How to access Onpattro from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient (or diaspora family supporting a relative in India) diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Onpattro (patisiran) from their treating neurologist. Onpattro is FDA-approved for this indication and developed by Alnylam Pharmaceuticals. In India, Onpattro is not routinely available through the local supply chain for this indication, so patients are typically routed through the named-patient / personal-use import pathway.
This guide explains the legal pathway, documentation your physician prepares, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Onpattro in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Onpattro is a lipid-nanoparticle-encapsulated siRNA that silences hepatic TTR production, administered by intravenous infusion every three weeks. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and cardiac workup to characterise any ATTR-CM overlap. Your neurologist will establish baseline neuropathy impairment score, NIS+7, polyneuropathy disability score, and quality-of-life measures. Onpattro infusion requires a premedication regimen (corticosteroid, antihistamine, acetaminophen) and a clinic with infusion capability; many Indian tertiary centres can accommodate.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Onpattro legally importable into India?
Yes, through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a well-established personal-use import mechanism regularly used for rare-disease therapies, including those without a locally registered alternative. A registered medical practitioner, or the patient on personal-use grounds with physician documentation, may request import of a medicine approved by a recognised reference authority where no clinically equivalent registered alternative exists. hATTR polyneuropathy has limited disease-specific registered options in India.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and a clinical rationale documenting the absence of locally registered alternatives.
- Baseline assessment. NIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP), and infusion-centre identification.
- CDSCO personal-use / named-patient application. The physician or hospital files clinical rationale, genetic report, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Onpattro from authorised distribution under DSCSA.
- Cold-chain shipment. Onpattro is a refrigerated product; shipment follows validated cold-chain protocols with temperature logging and customs clearance support.
- Arrival and infusion. The hospital pharmacy receives the vial; the infusion centre administers the dose with the on-label premedication regimen.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Onpattro as the indicated therapy
- Verification of Indian medical registration (NMC)
- TTR genetic test result
- Baseline NIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Planned infusion schedule (every 3 weeks) and premedication plan
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers and Indian customs expect to see for rare-disease named-patient imports.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, customs clearance, CDSCO documentation handling, cold-chain shipment, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: hATTR is an autosomal-dominant hereditary disease, and Indian families commonly take shared responsibility for long-term care decisions across generations and continents. Our team coordinates with whichever family members, a parent in Chennai, a sibling in New Jersey, a cousin in Dubai, the patient designates.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO / customs review.
- Logistics. Validated cold-chain shipment with customs clearance support.
- Dedicated case lead. A named point of contact for long-term infusion-cycle refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. See our trust and compliance page.
Does my centre need infusion capability? Yes, Onpattro is IV-infused with on-label premedication. Your neurologist will confirm the infusion-capable centre before intake.
Can diaspora family pay directly? Yes. Cross-border payment is common; we issue invoicing that family in the US, UK, UAE, Canada, and Australia can settle directly.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Onpattro in India if it is not approved or available there?
Reserve Meds coordinates US-sourced Onpattro for patients in India through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for India and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Onpattro in India through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Onpattro. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in India, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Onpattro in India through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Onpattro to a patient in India?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Onpattro to your treating physician or hospital pharmacy in India, with appropriate handling for the product.
How long does it take, and what does Onpattro in India cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Onpattro in India?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.